Comparative Pharmacology
Head-to-head clinical analysis: BAXDELA versus CINOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAXDELA versus CINOXACIN.
BAXDELA vs CINOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Oral: 450 mg (as single tablet) twice daily for 5 days. Intravenous: 450 mg once daily (over 3 hours) or 300 mg twice daily (over 1 hour) for 5 days.
1 g orally twice daily for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours in healthy adults; may be prolonged in patients with renal impairment (up to 20 hours in severe renal impairment).
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digitoxin
"Cinoxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCinoxacin + Deslanoside
"Cinoxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCinoxacin + Acetyldigitoxin
"Cinoxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Renal (approximately 65% of dose as unchanged drug) and fecal (approximately 20% as metabolites and unchanged drug). Biliary excretion is minimal.
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic